Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has issued an announcement.
Recordati reported first-quarter 2026 consolidated net revenues of €713.4 million, up 4.9% overall and 8.7% on a like-for-like basis at constant exchange rates, driven chiefly by strong growth in its Rare Diseases business. EBITDA rose 5.0% to €283.6 million, adjusted net income increased 7.2% to €188.1 million, and net income jumped 22.4%, although free cash flow fell and net debt reached €1.99 billion, while the group confirmed its full-year 2026 financial targets.
Rare Diseases revenues climbed 14.8% to €292.4 million, propelled by robust volume growth in endocrinology and onco-haematology, with Isturisa and Enjaymo posting particularly strong gains, while the metabolic franchise declined due to timing effects and softer demand for some products. Specialty and Primary Care revenues were broadly stable on a like-for-like basis despite some expected one-offs, and Recordati advanced its pipeline by achieving the primary endpoint in a phase 2 study of pasireotide for post-bariatric hypoglycaemia and moving sutimlimab into phase 3 for chronic immune thrombocytopenia, underlining its strategic focus on rare disease innovation and long-term growth.
The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian pharmaceutical group focused on rare diseases and specialty and primary care medicines, with key franchises in endocrinology, onco-haematology, metabolic disorders, cardiovascular, gastrointestinal, urology and influenza-related therapies. The company has a strong and growing presence in target markets, particularly in the United States, where it is expanding its rare disease portfolio, including drugs such as Isturisa, Signifor, Enjaymo and Qarziba.
Average Trading Volume: 391,454
Technical Sentiment Signal: Strong Buy
Current Market Cap: €10.32B
See more data about REC stock on TipRanks’ Stock Analysis page.